On Wednesday, August 17th, the FDA issued a final rule regarding when a substance is generally recognized as safe. FDA states that the final rule is intended to amend and clarify the criteria in its regulations concerning “when the use of a substance in food for humans or animals is not subject to the premarket approval requirements of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) because the substance is generally recognized as safe (GRAS) under the conditions of its intended use.”
In its notice, FDA announced that it is also replacing the voluntary GRAS affirmation petition process with a voluntary notification procedure under which any person may alert the Agency of a conclusion that a substance is GRAS under the conditions of its intended use.
FDA notes that the clarified criteria will allow stakeholders to make more informed conclusions regarding whether or not a substance’s intended conditions of use comply with the FD&C Act. Furthermore, FDA’s notification procedure will inform stakeholders as to whether the FDA is questioning the basis of a conclusion of GRAS status.
For more information and a detailed explanation of the Agency’s amended regulations, view FDA’s final rule.
August 29, 2016
On Wednesday, August 24th FDA released a final guidance document, entitled “Abbreviated New Drug Application Submissions – Refuse to Receive for Lack of Justification of Impurity Limits,” which...
October 22, 2018
On Friday, October 12th, FDA issued a guidance document entitled “Impact of Certain Provisions of the Revised Common Rule on FDA-Regulated Clinical Investigations.” The document aims to help...
August 31, 2015
Earlier this year, FDA published a report announcing that the Agency’s device program has shown “a pattern of markedly improved performance.” Over the past five years, FDA has been working to improve...